https://de.marketscreener.com/kurs/aktie/FORESEE-PHARMACEUTICALS-C-45304233/news/Foresee-Pharmaceuticals-wird-das-Design-der-klinischen-Phase-1-2-Fanconi-Anamie-Studie-fur-seinen-44959040/?utm_source=telegram&utm_medium=social&utm_campaign=share